iBio
IBIO
28 hedge funds and large institutions have $11.5M invested in iBio in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
3,229% more capital invested
Capital invested by funds: $345K → $11.5M (+$11.1M)
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
65.08% more ownership
Funds ownership: 17.83% → 82.91% (+65%)
33% more funds holding
Funds holding: 21 → 28 (+7)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$855K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$754K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$754K |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$754K |
| 5 |
AC
Armistice Capital
New York
|
+$441K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$205K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$34.8K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$26.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$20.3K |
| 5 |
BlackRock
New York
|
-$1.35K |
IBIO Hedge Fund Activity: Q1 2024 in Review
28 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2024, worth a combined $11.5M — up 3,229% from $345K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IBIO positions and 3 closed out — a net gain of 7 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $855K. The largest seller was Sabby Management, cutting an estimated $205K.
- 28 institutional investors held iBio (IBIO) as of Q1 2024, up from 21 in Q4 2023.
- Funds reported $11.5M of iBio stock for Q1 2024, up 3,229% quarter-over-quarter.
- 10 funds opened new iBio positions in Q1 2024 and 3 closed out, a net change of +7 holders.
- The largest iBio buyer in Q1 2024 was Opaleye Management, an estimated $855K added.
- The largest iBio seller in Q1 2024 was Sabby Management, an estimated $205K sold.
Based on aggregated 13F filings for Q1 2024.